Raw and Starting Materials – Foreword

Cell & Gene Therapy Insights 2019; 5(2), 147-148.


Published: 1 April 2019
Robert G Piperno

Robert G Piperno

Robert G Piperno is the Director of CGT Quality Assurance in the Global Pharma QA organization. In this role he is responsible for providing the global quality oversight and management of internal and external activities supporting clinical and commercial Cell and Gene Therapy Products, including the approval of STRIMVELIS™ by EMA. Rob joined GSK in 2009 as part of the Corporate Audit and Assurance function and transitioned to R&D QA in 2012, and to CGT QA in 2014. He has over 20 years of experience in the pharmaceutical industry and prior to GSK he was employed at Johnson & Johnson for 9 years holding positions including, site quality operations and leading a corporate team supporting the management of external partners and CMOs. Rob has a Bachelor’s and Master’s degree in Biology from Rutgers University and an MBA in Pharmaceutical Management from St. Joseph’s University.